Overview

Gender

male

Faheem Hasnain is the Chairman of the Board of directors at Ambit Biosciences Corporation. Faheem Hasnain has served as one of our directors since October 2010, and as the chairman of the board since November 2010.

Faheem Hasnain is the president and chief executive officer of Receptos, Inc., a drug discovery and development company, a position he has held since December 2010.From December 2008 until its acquisition by Abbott Laboratories in April 2010, he was the president and chief executive officer and a director of Facet Biotech Corporation, a publicly-traded, biology-driven antibody company with a focus in oncology and multiple sclerosis.

Faheem Hasnain was president, chief executive officer and a director of PDL BioPharma, Inc., a publicly-traded biotechnology company, from October 2008 until Facet Biotech was spun off from PDL BioPharma in December 2008.

From October 2004 to September 2008, Faheem Hasnain served at Biogen Idec Inc., a biotechnology company specializing in neurological disorders, autoimmune disorders and cancer, most recently as executive vice president in charge of the oncology/rheumatology strategic business unit.

Prior to Biogen Idec, Faheem Hasnain held roles with Bristol-Myers Squibb, where he was president of the oncology therapeutics network, and for 14 years at GlaxoSmithKline plc and its predecessor organizations. Faheem Hasnain has served on the board of directors of Somaxon Pharmaceuticals, Inc., a publicly-traded specialty pharmaceutical company, since September 2010.

Faheem Hasnain received a B.H.K. and B.Ed. from the University of Windsor Ontario in Canada.